Antibody-drug conjugates (ADCs) are a new class of biotherapeutics, consisting of acytotoxic payload covalently bound to an antibody by a linker. Evaluating the pharmacokinetics (PK) properties of ADCs in preclinical and clinical studies is essential for their strategic design and successful development.
Epsilogen Ltd completes £12.5m Series B expansion
Latest NewsA new £12.5m Series B expansion brings Elipsogen Ltd’s total Series B funds raised to £43.25 million. The IgE antibody specialist will use the roceeds to support the delivery of clinical Proof of Concept for MOv18 IgE.
Swiss RNA maker Haya in huge licence deal
Latest NewsSwiss HAYA Therapeutics SA has inked a US$1bn biobuck deal with pharma giant Eli Lilly to discover new lncRNA targets in obesity and related metabolic conditions.
Roche with good interim clinical results
Latest NewsRoche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression after one year in patients with relapsing multiple sclerosis
Individor set to waive AEF0117 licence after Phase IIb failure
Latest NewsFollowing the failure of Aelis Farma’s lead candidate AEF0117 in a Phase IIb study in patients with cannabis use disorder or cannabis-induced psychosis, Individor plc has stated that it will not exercise its licence option until Aelis has submitted a final data analysis.
Nxera Pharma Ltd collects clinical US$35m milestone
Latest NewsNxera Pharma Ltd has got a Phase II milestone from US licencor Neurocrine Biosciences for its first-in class oral schizophrenia candidate NBI-1117568.
Anti-payload Antibodies: Facilitating ADC PK studies
Sponsored PublicationsAntibody-drug conjugates (ADCs) are a new class of biotherapeutics, consisting of acytotoxic payload covalently bound to an antibody by a linker. Evaluating the pharmacokinetics (PK) properties of ADCs in preclinical and clinical studies is essential for their strategic design and successful development.
Researchers present AI-guided protein design tool
Latest NewsDanish AI expert Francesco Pesce and collegues have expanded the toolbox for computational protein design. Their new algorithm will facilitate the design of proteins whose functions exploit the many properties afforded by protein disorder.
Amferia partners with Biokema expanding into Switzerland
Latest NewsSwedish antimicrobial specialist Amferia AB has inked a contract is with the Swiss animal health company Biokema SA for commercialisation of Amferia’s proprietary antimicrobial wound care technology in Switzerland.
Confusion in Germany about useful genetic testing
Latest NewsThe extent to which vested interests can delay innovation can currently be seen in the introduction of screening for the dominantly inherited disease familial hypercholesterolaemia, the benefits of which have already been proven in the UK and the Netherlands.
AAX Biotech strengthens Board of Directors
AppointmentsSwedish biotech company AAX Biotech AB has welcomed Patrik Strömberg as a new member of the Board of Directors.